Cipla Limited has informed the Exchange about USFDA inspection at Company's manufacturing facility in Goa, India

Regulatory & Legal View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹1244.50

prior close

₹1245.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.1%-1.3% vs market

Pharmaceuticals peers, median of 156sector-0.9%-0.4% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty 100 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.2

15m

-0.4

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.1-1.3-0.9-0.4

Next day

-0.9+0.9-1.8-0.7-0.1

-0.4+0.4-0.7-0.2-0.2

+5.0-0.6+5.6+0.0+5.0

+4.1-1.6+5.8-1.2+5.3

+5.7-0.7+6.4+0.0+5.7

+5.5-0.5+6.0-0.1+5.6

15d

+4.0-3.7+7.7+1.7+2.2

+12.5-2.6+15.1+2.3+10.2

+13.9-0.1+14.0+6.3+7.6

+15.4+0.2+15.2+12.0+3.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA inspected Cipla's manufacturing plant in Verna, Goa from April 6 to April 17, 2026. The inspection covered both routine cGMP compliance and a Pre-Approval Inspection (PAI) for new product approvals. At the end of the inspection, Cipla received a Form 483 with 2 observations. The company has stated it will work with the USFDA to address these observations within the stipulated timeframe. No warning letter or import alert has been issued. The Goa facility is one of Cipla's key manufacturing sites supplying medicines to the US market.

Likely market impact

A Form 483 with only 2 minor observations is relatively benign for a pharma company and the stock is unlikely to see a sharp negative reaction. However, since the inspection also included a Pre-Approval Inspection, the outcome could influence the timeline for certain pending US product approvals. Investors should watch for further updates on whether the observations are resolved without escalation.